If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Rule 2.9 Announcement

19 May 2022 14:01

RNS Number : 1477M
Ideagen PLC
19 May 2022
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

19 May 2022

 

Ideagen PLC

("Ideagen" or the "Company")

Rule 2.9 Announcement

As announced earlier today, the Company allotted a total of 3,955 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") on 18 May 2022 following purchases made under the Company's Share Incentive Plan ("SIP"). 

Following issue of the Ordinary Shares, the number of Ordinary Shares in issue and admitted to trading on AIM will be 293,753,784. This figure of 293,753,784 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Ordinary Shares are relevant securities of Ideagen plc for the purposes of Rule 8 of The City Code on Takeovers and Mergers (the "Code"). In accordance with Rule 2.9 of the Code, Ideagen confirms that it has in issue 293,753,784 Ordinary Shares and admitted to trading on the AIM Market of the London Stock Exchange. The Company has no Ordinary Shares held in Treasury. The International Securities Identification Number for Ideagen Ordinary Shares is GB00B0CM0C50. 

 

Enquiries:

Ideagen plcBen Dorks, Chief Executive OfficerEmma Hayes, Chief Financial Officer

01629 699 100

 

 

Goldman Sachs International (Financial Adviser to Ideagen)

Chris EmmersonKhamran Ali

020 7774 1000

 

 

Canaccord Genuity Limited (Nomad)Simon Bridges

Georgina McCooke

020 7523 8000

 

FTI ConsultingJamie RickettsDwight BurdenValerija Cymbal

020 3727 1000

ideagen@fticonsulting.com

 

About Ideagen plc

Ideagen's software helps companies comply with regulation and manage risk.

Ideagen is a leader in the +$30 billion regulatory and compliance software market, serving highly regulated industries such as life sciences, healthcare, banking and finance and insurance. 

More than 8,000 customers use Ideagen's software, including leading accounting and pharmaceutical firms.

Ideagen has a track record of 12 years of profitable growth and strong cash generation with high levels of recurring revenues (representing an expected 86% of total revenues for the year ended 30 April 2022).

Ideagen has a diversified customer base including blue chip, global brands such as Heineken, British Airways, Aggreko, Bank of New York and Johnson Matthey.

Ideagen is headquartered in the UK, listed on the London Stock Exchange AIM market (Ticker: IDEA.L), and has key hubs in the UK, USA, Middle East and South East Asia. For further information please visit www.ideagen.com.

 

Miscellaneous

 

Goldman Sachs International, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Ideagen and no one else in connection with the matters set out in this announcement and will not be responsible to anyone other than Ideagen for providing the protections afforded to clients of Goldman Sachs International nor for providing advice in connection with the contents of this announcement or any other matter referred to herein.

Canaccord Genuity Limited ("Canaccord Genuity"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for Ideagen and no one else in connection with the matters set out in this announcement and will not be responsible to anyone other than Ideagen for providing the protections offered to clients of Canaccord Genuity or for providing advice in relation to the contents of this announcement or any matters referred to herein.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTTBKCBPBBKDAPD
Date   Source Headline
26th Jan 201610:43 amRNSDirector/PDMR Shareholding
26th Jan 20167:00 amRNSInterim Results
13th Jan 20161:41 pmRNSHolding(s) in Company
22nd Dec 20157:00 amRNSExercise of Options and Total Voting Rights
11th Dec 20159:53 amRNSHolding(s) in Company
25th Nov 20151:42 pmRNSHolding(s) in Company
24th Nov 20157:00 amRNSHolding(s) in Company
19th Nov 20157:00 amRNSTrading Update
5th Nov 201511:23 amRNSChange of Registered Office Address
29th Oct 20153:59 pmRNSResult of AGM
20th Oct 20157:00 amRNSExercise of Options
7th Oct 20157:00 amRNSNotice of AGM
23rd Sep 20158:15 amRNSEnlighten product wins GRC Innovation Award
3rd Sep 20157:00 amRNSNew Contract Extensions worth £1m
10th Aug 20157:00 amRNSExercise of Options and Total Voting Rights
31st Jul 201511:54 amRNSDirector Dealing
23rd Jul 20157:00 amRNSGrant of Share Options
22nd Jul 20157:00 amRNSFinal Results
9th Jul 20157:00 amRNSNotice of Results
30th Jun 20159:19 amRNSShares Magazine Investor Event
3rd Jun 201511:25 amRNSHolding(s) in Company
21st May 20157:00 amRNSG-Cloud Award and New Contract Win
14th May 20157:00 amRNSPre-Close Trading Update
7th May 20157:00 amRNSExercise of Options and Total Voting Rights
30th Apr 201510:26 amRNSHolding(s) in Company
23rd Apr 201511:55 amRNSHolding(s) in Company
20th Apr 20152:53 pmRNSReplacement Director Dealing & Total Voting Rights
20th Apr 20157:00 amRNSDirector Dealing & Total Voting Rights
15th Apr 201511:25 amRNSHolding(s) in Company
11th Mar 201511:23 amRNSHolding(s) in Company
6th Mar 201512:57 pmRNSHolding(s) in Company
25th Feb 20157:00 amRNSExercise of Options and Total Voting Rights
24th Feb 20157:00 amRNSNew Aviation Contract Wins worth £1m
29th Jan 20157:00 amRNSInterim Results
20th Jan 20153:41 pmRNSHolding(s) in Company
16th Jan 201512:44 pmRNSHolding(s) in Company
16th Jan 201512:42 pmRNSHolding(s) in Company
13th Jan 20151:04 pmRNSCompletion of Acquisition of Gael Limited
9th Jan 201511:55 amRNSHolding(s) in Company
7th Jan 201512:56 pmRNSResult of General Meeting
18th Dec 20147:00 amRNSAcquisition, Placing and Notice of General Meeting
13th Nov 20147:00 amRNSTrading update and Notice of Results
5th Nov 20148:30 amRNSIdeagen selected by NuGen
31st Oct 20141:47 pmRNSResult of AGM
9th Oct 20147:00 amRNSNotice of 2014 Annual General Meeting ("AGM")
2nd Oct 20147:00 amRNSContract Win and Trading Update
4th Aug 20147:00 amRNSIssue of Equity
22nd Jul 20147:00 amRNSFinal Results
10th Jul 20147:00 amRNSNotice of Results
25th Jun 20147:01 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.